Growth Equity Opportunities Fund IV, LLC 13D and 13G filings for Verona Pharma plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-21 8:33 pm Sale | 2025-01-16 | 13D | Verona Pharma plc VRNA | Growth Equity Opportunities Fund IV, LLC | 32,679,649 4.990% | -11,998,376 (-26.86%) | Filing |
| 2024-08-28 9:51 pm Sale | 2022-09-07 | 13D | Verona Pharma plc VRNA | Growth Equity Opportunities Fund IV, LLC | 44,678,025 6.900% | -1,769,626 (-3.81%) | Filing |
| 2022-09-07 5:28 pm Purchase | 2022-08-15 | 13D | Verona Pharma plc VRNA | Growth Equity Opportunities Fund IV, LLC | 46,447,651 7.900% | 3,809,520 (+8.93%) | Filing |
| 2020-08-03 4:18 pm Purchase | 2020-07-22 | 13D | Verona Pharma plc VRNA | Growth Equity Opportunities Fund IV, LLC | 42,638,131 10.200% | 31,111,112 (+269.90%) | Filing |